Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
about
HIV-1 prophylactic vaccines: state of the artRecent Advances in Lentiviral Vaccines for HIV-1 InfectionMethods and clinical development of adenovirus-vectored vaccines against mucosal pathogensApproaches to preventative and therapeutic HIV vaccinesWhich New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Role of HLA Adaptation in HIV EvolutionSystems Biology Approach for Cancer Vaccine Development and EvaluationApplication of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesBone Marrow Gene Therapy for HIV/AIDSVaccines for the 21st centuryAntiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory AntibodiesNew concepts in HIV-1 vaccine developmentAdult immunization-Need of the hourRecent developments in clinical trial designs for HIV vaccine researchMeasurements of immune responses for establishing correlates of vaccine protection against HIVA Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Recent Insights into the HIV/AIDS Pandemic.Human parvovirus 4 'PARV4' remains elusive despite a decade of studyHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentCurrent views on the potential for development of a HIV vaccine.Controlling the HIV/AIDS epidemic: current status and global challengesEfficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis TrialHIV-1 vaccines: challenges and new perspectivesInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Novel directions in HIV-1 vaccines revealed from clinical trialsVaccine-induced myeloid cell population dampens protective immunity to SIVNonreplicating vectors in HIV vaccines.Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239Systems-level analysis of innate immunity.Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trialsVaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.The influence of delivery vectors on HIV vaccine efficacyWHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis.First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individualsImmunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
P2860
Q26740042-9C1C05EE-D4E8-4166-9BB5-DA03E0D4171EQ26742169-AC530074-E048-4196-947A-0669AC643853Q26750912-028BF860-AA98-4718-B409-966A3F65A6F0Q26764851-D6DF289C-D491-4503-8AFA-F7D472D308B5Q26765043-C0F71FD6-D14A-43A6-BF57-3AF2340EB8CAQ26772713-00E3DAC0-0298-4B2E-95C5-9A91CD7DB02CQ26782580-B822E94C-05B2-4A68-88B4-BB94932A36DFQ26783957-232B005C-9E24-40F8-9952-8EEC4D9FC79DQ26801765-7F8AF97A-0C2C-4F20-BB7F-81A9D270CF53Q27007529-B009B3F8-4730-424D-9B63-195F2F6127D0Q28066335-30F87B68-CACE-4B93-B6C8-0E72A4770BA6Q28067027-D7FF8F89-8226-4313-8950-D094958CD9A4Q28077096-7B079111-CC6B-469D-83DE-92EB46784D74Q28083514-0ED61CE2-E786-464F-97A6-8741F3F40DEFQ28728189-4707245A-4DDE-4F33-B441-782EDB0CBAA5Q30234577-E2F90D8C-0E76-4679-A3B1-0303BE3E3F13Q30235024-9B6F42CE-1D99-4A26-AF5B-2D5BA88241E6Q30238496-4C840C54-5FE4-4488-80C8-F62C82DF8C98Q30355260-60EDB9E0-96FA-4B8C-BC21-6AF983784FDAQ30397595-36216418-9884-4E77-BC14-9E30A0B41599Q30420558-9C5C5FB1-39E8-4FFB-A496-4DC8696CB4D0Q30578618-7B7AC019-715C-4E5D-B3C4-581C6E2428F2Q33574027-2994BE2D-24D6-408A-A427-E8951B231956Q33577972-448E5DB5-C450-4FE1-B69D-025B1A5BA374Q33611645-B129B4DC-F3B4-4806-9AFE-4677E49541D5Q33645528-D706CBF6-BBC9-443E-AD8F-24C7234F1A33Q33685961-24280354-8B6E-489C-95E0-603D8C99D883Q33693891-BEA1B858-E883-4613-9838-3FD2A3698A3AQ33742529-0DB73677-4672-4D1F-B74B-9D4DE0581D7FQ33744109-2038FEA1-78A0-411C-A8DC-AD286ED00988Q33855179-44E05B76-7D60-48D3-986E-14D013179F10Q33999615-B5492E45-90BB-4086-AA3A-ECC323C26EEFQ34055991-D26A5461-3232-4389-B917-33DECE9646EAQ34059103-F08E18E4-0D7A-4F0C-84BA-A8581B3C9C08Q34077543-E321D38F-000A-4C9F-AE34-46601A54D680Q34180631-B1EC4D9E-3E01-4EE3-BDC1-BC4D2C21A2A7Q34209026-359A7CBE-55C8-4882-861C-10D07AEA8683Q34218500-101623E1-B95C-4568-9CB8-D0F366424B99Q34229329-E80D9D1D-5175-4558-B7D9-340084930BE4Q34240204-371B4A86-A264-4A66-AED9-FA34AF0CECA9
P2860
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@ast
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@en
type
label
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@ast
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@en
prefLabel
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@ast
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@en
P2093
P2860
P50
P1476
Safety and efficacy of the HVT ...... est-of-concept phase 2b study.
@en
P2093
Adrien Puren
Barbara Metch
Constance Ducar
Donald K Carter
Gavin Churchyard
Glenda E Gray
Guy de Bruyn
HVTN 503/Phambili study team
James G Kublin
M Julie McElrath
P2860
P304
P356
10.1016/S1473-3099(11)70098-6
P577
2011-05-11T00:00:00Z